Under the terms of its agreement with Johns Hopkins, PGDx has the right to sub-license the DK technology to third parties.
Mr. Newton was recently recruited to PGDx after a 19-year career at Genzyme Corporation, where he held a number of roles in marketing, commercial development and drug development. He was most recently Vice President in the Oncology Division.
PGDx, which was originally located in the Johns Hopkins Science and Technology Park, has moved into larger laboratory and office facilities along the Inner Harbor area of Baltimore.
For more information on PGDx, visit: www.personalgenome.com/.
About Personal Genome Diagnostics
Personal Genome Diagnostics (PGDx) provides advanced genome-mapping services and analyses to oncology researchers, clinicians and patients. The company was founded in 2010 by international leaders in cancer genetics at Johns Hopkins University. PGDx conducts patient-specific analyses aimed at identifying the unique genomic alterations in tumors and linking them to the underlying biology. PGDx employs cancer exome analysis, which enables comprehensive and reliable genome-wide identification of cancer-related mutations. The company's proprietary methods for genome sequencing and analysis are complemented by its deep expertise in cancer genomics. PGDx's CLIA-certified facility provides personalized cancer genome analyses to patients and their physicians. For more information, visit www.personalgenome.com.
MediaPersonal Genome Diagnostics
BLL Partners, LLC Antony Newton
Barbara Lindheim <
|SOURCE Personal Genome Diagnostics Inc.|
Copyright©2012 PR Newswire.
All rights reserved